8467 related articles for article (PubMed ID: 12371273)
1. [Identification of cancer antigens of relevance for specific cancer immunotherapy].
van den Eynde B
Bull Mem Acad R Med Belg; 2001; 156(10-12):548-55. PubMed ID: 12371273
[TBL] [Abstract][Full Text] [Related]
2. What's new in the field of cancer vaccines?
Renno T; Lebecque S; Renard N; Saeland S; Vicari A
Cell Mol Life Sci; 2003 Jul; 60(7):1296-310. PubMed ID: 12943219
[TBL] [Abstract][Full Text] [Related]
3. Prerequisites for the immunotherapy of cancer.
Pawelec G; Engel A; Adibzadeh M
Cancer Immunol Immunother; 1999 Jul; 48(4):214-7. PubMed ID: 10431692
[TBL] [Abstract][Full Text] [Related]
4. Facts and Hopes in Immunotherapy Strategies Targeting Antigens Derived from KRAS Mutations.
Linette GP; Bear AS; Carreno BM
Clin Cancer Res; 2024 May; 30(10):2017-2024. PubMed ID: 38266167
[TBL] [Abstract][Full Text] [Related]
5. Targets for active immunotherapy against pediatric solid tumors.
Jacobs JF; Coulie PG; Figdor CG; Adema GJ; de Vries IJ; Hoogerbrugge PM
Cancer Immunol Immunother; 2009 Jun; 58(6):831-41. PubMed ID: 19009292
[TBL] [Abstract][Full Text] [Related]
6. Monitoring of antigen-specific cytolytic T lymphocytes in cancer patients receiving immunotherapy.
Whiteside TL
Clin Diagn Lab Immunol; 2000 May; 7(3):327-32. PubMed ID: 10799441
[No Abstract] [Full Text] [Related]
7. Tumor stroma-associated antigens for anti-cancer immunotherapy.
Hofmeister V; Vetter C; Schrama D; Bröcker EB; Becker JC
Cancer Immunol Immunother; 2006 May; 55(5):481-94. PubMed ID: 16220326
[TBL] [Abstract][Full Text] [Related]
8. New methods to approach immunotherapy of cancer--and strategies of tumours to avoid elimination. Conference report, on behalf of EUCAPS. European Cancer Research Consortium.
Pawelec G
Cancer Immunol Immunother; 2000 Jul; 49(4-5):276-80. PubMed ID: 10941911
[TBL] [Abstract][Full Text] [Related]
9. Multivesicular liposomes containing bleomycin for subcutaneous administration.
Roy R; Kim S
Cancer Chemother Pharmacol; 1991; 28(2):105-8. PubMed ID: 1711933
[TBL] [Abstract][Full Text] [Related]
10. Heterogeneity of cytokine production by human malignant melanoma cells.
Armstrong CA; Tara DC; Hart CE; Köck A; Luger TA; Ansel JC
Exp Dermatol; 1992 Jul; 1(1):37-45. PubMed ID: 1344659
[TBL] [Abstract][Full Text] [Related]
11. Potential side effects of dendritic cells pulsed with allogenic melanoma cell lysate in mice.
Park SY; Choi WH; Kim YB; Ha CS; Lee H; Kwon YD; Choi OM; Lee YJ; Koh WS
Int J Toxicol; 2007; 26(1):33-40. PubMed ID: 17365144
[TBL] [Abstract][Full Text] [Related]
12. Effect of local tumor irradiation and interleukin-2 therapy in different murine tumors.
Lam JS; Hillman GG; Younes E; Ali E; Maughan RL; Montecillo EJ; Pontes JE; Haas GP
J Immunother Emphasis Tumor Immunol; 1995 Jul; 18(1):28-34. PubMed ID: 8535568
[No Abstract] [Full Text] [Related]
13. A combination of subcutaneous recombinant interleukin-2 and recombinant interferon-alpha in the treatment of advanced renal cell carcinoma or melanoma.
Vuoristo M; Jantunen I; Pyrhönen S; Muhonen T; Kellokumpu-Lehtinen P
Eur J Cancer; 1994; 30A(4):530-2. PubMed ID: 8018415
[TBL] [Abstract][Full Text] [Related]
14. Selective cytotoxicity of a ricin A-chain-anti-carcinoembryonic antigen antibody conjugate for a human colon adenocarcinoma cell line.
Griffin TW; Haynes LR; DeMartino JA
J Natl Cancer Inst; 1982 Oct; 69(4):799-805. PubMed ID: 6956757
[TBL] [Abstract][Full Text] [Related]
15. Monoclonal antibodies against human malignant melanoma.
Sorg C; Brüggen J; Suter L; Bröcker EB
Bull Cancer; 1983; 70(2):113-7. PubMed ID: 6871486
[TBL] [Abstract][Full Text] [Related]
16. Metastatic malignant melanoma: regression induced by combined treatment with interferon [HuIFN-alpha(Le)] and cimetidine.
Flodgren P; Borgström S; Jönsson PE; Lindström C; Sjögren HO
Int J Cancer; 1983 Dec; 32(6):657-65. PubMed ID: 6654521
[TBL] [Abstract][Full Text] [Related]
17. [Distribution of DL-3 (3,4-dihydroxyphenyl)-alanine-2 C14 in the organism of mice with Cloudmann's S91 melanoma].
Delacretaz J; Emch M; Schellhorn JP
Arch Belg Dermatol Syphiligr; 1970; 26(2):261-70. PubMed ID: 5515554
[No Abstract] [Full Text] [Related]
18. BM 41.440: a new antineoplastic, antimetastatic, and immune-stimulating drug.
Herrmann DB; Bicker U; Pahlke W
Cancer Detect Prev Suppl; 1987; 1():361-71. PubMed ID: 3480059
[TBL] [Abstract][Full Text] [Related]
19. Growth and dissemination of human malignant melanoma cells in mice with severe combined immune deficiency.
Taylor CW; Grogan TM; Lopez MH; Leong SP; Odeleye A; Feo-Zuppardi FJ; Hersh EM
Lab Invest; 1992 Jul; 67(1):130-7. PubMed ID: 1625443
[TBL] [Abstract][Full Text] [Related]
20. Comparative analysis of clinicopathological and immunohistochemical characteristics of Merkel cell carcinoma.
Trenkic Bozinovic M; Krasic D; Katic V; Rancic D; Krstic M; Jocic Djordjevic J; Jovanovic J
J BUON; 2014; 19(2):530-4. PubMed ID: 24965417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
